MoonLake shares crash 88% after mixed trial results raise doubts over skin drug
MoonLake Immunotherapeutics(US:MLTX) Invezz·2025-09-29 13:02Shares of Swiss biotech MoonLake Immunotherapeutics tumbled 88% to $7.45 in premarket trading on Monday after the company reported mixed outcomes from two late-stage trials of its experimental skin dr... ...